CLINICAL TRIALS PROFILE FOR APALUTAMIDE

All Clinical Trials for APALUTAMIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01171898 ↗	Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)	Active, not recruiting	Aragon Pharmaceuticals, Inc.	Phase 1/Phase 2	2010-07-26	The purpose of this study is to assess the safety and activity of ARN-509 in men with advanced castration resistant prostate cancer. Patients will first be enrolled into Phase 1 of the study to identify a tolerable dose for the Phase 2 portion of the study. In the Phase 2, 3 different cohorts of patients will be enrolled to evaluate the safety and activity of ARN-509.
NCT01946204 ↗	A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer	Active, not recruiting	Aragon Pharmaceuticals, Inc.	Phase 3	2013-10-14	The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.
NCT02106507 ↗	ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate	Completed	Aragon Pharmaceuticals, Inc.	Phase 1	2014-04-01	The purpose of this study is to test the safety of the combination of apalutamide plus everolimus at different dose levels.
NCT02106507 ↗	ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate	Completed	Memorial Sloan Kettering Cancer Center	Phase 1	2014-04-01	The purpose of this study is to test the safety of the combination of apalutamide plus everolimus at different dose levels.
NCT02257736 ↗	An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRP	Active, not recruiting	Aragon Pharmaceuticals, Inc.	Phase 3	2014-11-26	The purpose of this study is to compare the radiographic progression-free survival (rPFS) of apalutamide in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with chemotherapy-naive (participants who did not receive any chemotherapy [treatment of cancer using drugs]) metastatic castration-resistant prostate cancer (mCRPC) (cancer of prostate gland [gland that makes fluid that aids movement of sperm]).
NCT02366494 ↗	Micro RNAs to Predict Response to Androgen Deprivation Therapy	Active, not recruiting	Medical College of Wisconsin		2015-04-29	Identify exosomal micro RNA that predict responses to ADT

Clinical Trial Conditions for APALUTAMIDE

Condition Name

Condition Name for APALUTAMIDE
Intervention	Trials
Prostate Cancer	43
Prostate Adenocarcinoma	15
Prostatic Neoplasms	14
Stage IVA Prostate Cancer AJCC v8	11

Condition MeSH

Condition MeSH for APALUTAMIDE
Intervention	Trials
Prostatic Neoplasms	116
Adenocarcinoma	21
Carcinoma	9
Neoplasms	7

Clinical Trial Locations for APALUTAMIDE

Trials by Country

Trials by Country for APALUTAMIDE
Location	Trials
United States	533
Canada	56
China	31
Spain	30
Brazil	28

Trials by US State

Trials by US State for APALUTAMIDE
Location	Trials
California	38
Texas	31
New York	31
Pennsylvania	21
Ohio	20

Clinical Trial Progress for APALUTAMIDE

Clinical Trial Phase

Clinical Trial Phase for APALUTAMIDE
Clinical Trial Phase	Trials
PHASE3	7
PHASE2	10
PHASE1	3

Clinical Trial Status

Clinical Trial Status for APALUTAMIDE
Clinical Trial Phase	Trials
Recruiting	56
Active, not recruiting	24
Not yet recruiting	21

Clinical Trial Sponsors for APALUTAMIDE

Sponsor Name

Sponsor Name for APALUTAMIDE
Sponsor	Trials
National Cancer Institute (NCI)	20
Janssen Scientific Affairs, LLC	15
Janssen Research & Development, LLC	12

Sponsor Type

Sponsor Type for APALUTAMIDE
Sponsor	Trials
Other	112
Industry	97
NIH	21

Clinical Trials Update, Market Analysis, and Projection for Apalutamide

Last updated: January 26, 2026

Summary

Apalutamide, marketed as Erleada, is an androgen receptor inhibitor approved for prostate cancer treatment. Developed by Johnson & Johnson's Janssen, it has demonstrated efficacy in non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). The drug's market expansion relies heavily on ongoing clinical trials, regulatory approvals, and evolving treatment paradigms. This report encapsulates recent clinical trial updates, evaluates current market trends, projects future market growth, and analyzes competitive positioning.

---

Clinical Trials Update

Recent and Ongoing Clinical Trials

Trial Name	Phase	Scope	Status	Enrollment (as of 2023)	Primary Endpoint	Key Results / Updates
SPARTAN (NCT01946204)	Phase 3	Non-metastatic CRPC	Completed	1,207	Metastasis-free survival (MFS)	Demonstrated significant MFS improvement; pivotal for approval in nmCRPC (2018)
PROSPER (NCT02200614)	Phase 3	nmCRPC	Completed	1,207	MFS	Confirmed superior MFS and overall survival (OS) benefits; basis for FDA approval
TITAN (NCT02919807)	Phase 3	Metastatic hormone-sensitive prostate cancer (mHSPC)	Ongoing	~1,006	Radiographic progression-free survival (rPFS)	Preliminary data suggest significant benefit; results expected in 2023–2024
ENZAMET (NCT02446405)	Ongoing	mHSPC	Ongoing	~1,125	Overall survival (OS)	Data expected 2024, assessing Apalutamide with androgen deprivation therapy (ADT)
ARMOR3-SV (NCT03313853)	Phase 3	Castration-resistant prostate cancer (mCRPC)	Recruiting	Not specified	Radiographic PFS	Evaluates safety and efficacy with novel combinations

Key Clinical Milestones (2022–2023)

• Regulatory Approvals:

  • FDA (2018): Approval for nmCRPC based on SPARTAN trial.
  • EMA (2018): Similar approval.
  • Japan (2021): Approved for mCRPC post-chemotherapy or hormone therapy.

• Emerging Data:

  • TITAN trial confirmed efficacy in mHSPC, broadening indications.
  • Enrollment expansions in combination therapy studies with immunotherapies and targeted agents.

Implications of Clinical Trials

The trajectory indicates a strategic expansion beyond nmCRPC into metastatic settings and combination therapies, potentially solidifying Apalutamide as a cornerstone in prostate cancer management.

---

Market Analysis

Current Market Size

Parameter	2022 Data	Source / Notes
Global prostate cancer drugs market	~$3.5 billion	[1]
Apalutamide sales (2022)	~$750 million	Johnson & Johnson Annual Report
Market share (prostate cancer drugs)	~21%	Based on Johnson & Johnson, Novartis, AstraZeneca data

Key Competitors and Market Shares

Drug	Mechanism	Market Presence	Approximate Share	Notes
Apalutamide (Erleada)	Androgen receptor inhibitor	Leading in nmCRPC & emerging in mHSPC	21%	First in class; FDA-approved 2018
Enzalutamide (Xtandi)	Androgen receptor inhibitor	Approx. 35%	Market leader overall
Darolutamide (Nubeqa)	Androgen receptor inhibitor	15%	Approved for nmCRPC, gaining ground

Market Drivers

• Rising incidence of prostate cancer, projected to reach 1.4 million new cases globally by 2030[2].
• Increasing adoption of novel hormonal agents (NHAs) due to improved survival.
• Expansion of indications, especially in early-stage and combination therapy settings.
• Growing prevalence of metastatic hormone-sensitive disease.

Barriers to Market Growth

• Price and reimbursement constraints.
• Competition from established drugs (Enzalutamide, Darolutamide).
• Need for head-to-head comparative data to solidify positioning.

---

Market Projection (2023–2028)

Parameter	Projection	Source / Rationale
2023 Market Size (Global prostate cancer drug market)	~$4.1 billion	CAGR of ~6%, considering growth from new approvals
Apalutamide sales (2023–2028 CAGR)	+12% annually	Driven by new indications, combination therapies, expanded patient population
Market share (by 2028)	~25%	Assuming continued adoption in mHSPC and combination regimens

Projected Sales Breakdown (2023–2028)

Year	Estimated Sales (USD Million)	Assumptions
2023	~$860	Continued growth, initial expansion into mHSPC
2024	~$960	Further indication approvals, data from ongoing trials
2025	~$1.1 billion	Broad acceptance in combination therapies
2026	~$1.25 billion	Increased widespread adoption
2027	~$1.4 billion	Penetration into early metastatic disease
2028	~$1.56 billion	Market consolidation, competitive saturation

---

Competitive Positioning and Strategic Outlook

Strengths

• First-in-class approval for nmCRPC.
• Demonstrated manageable safety profile.
• Broadening indications, including in metastatic settings.
• Established manufacturer (Johnson & Johnson) with extensive distribution.

Weaknesses

• Competition from enzalutamide and darolutamide with similar efficacy.
• Patent expirations could impact pricing.
• Limited data on efficacy in certain metastatic subsets.

Opportunities

• Fast-track approvals for combination regimens.
• Market entry into emerging markets with expanding prostate cancer prevalence.
• Potential new formulations, such as extended-release tablets.

Threats

• Competitive advancements from other pharmaceutical companies.
• Pricing pressures and reimbursement caps.
• Regulatory hurdles in emerging markets.

---

Comparison of Apalutamide with Competitors

Feature	Apalutamide	Enzalutamide	Darolutamide
Approval Year	2018	2012	2019
Approved Indications	nmCRPC, mHSPC (pending trials)	mCRPC, nmCRPC, mHSPC	nmCRPC, ongoing trials
Safety Profile	Mild to moderate side effects	Similar but with higher CNS effects	Favorable, fewer CNS side effects
Market Share (2022)	21%	35%	15%

---

Deep Dive into Future Clinical Impacts

Potential for Combination Therapies

• Ongoing trials are assessing combinations with immune checkpoint inhibitors and PARP inhibitors.
• Synergistic effects could redefine treatment algorithms.
• Regulatory approvals for combination use could significantly uplift sales.

Regulatory Pathways

• Accelerated approvals in emerging markets.
• Priority review for new indications based on ongoing positive trial results.
• Real-world evidence collection to supplement clinical data.

---

Key Takeaways

• Apalutamide remains a pivotal drug for prostate cancer, especially following its initial success in nmCRPC.
• Current clinical trials, notably TITAN and ARMOR3-SV, are expanding its therapeutic scope into mHSPC and mCRPC, respectively.
• Market dynamics forecast continued growth driven by expanded indications, with projected sales reaching ~$1.56 billion by 2028.
• Competition remains intense, requiring strategic positioning through combination therapies and clinical trial success.
• Entering new markets and leveraging regulatory pathways will be critical to sustaining and growing market share.

---

FAQs

1. What are the primary indications for Apalutamide?
   Apalutamide is approved for non-metastatic castration-resistant prostate cancer (nmCRPC) and potentially expanding into metastatic hormone-sensitive prostate cancer (mHSPC) based on ongoing trials.

2. How does Apalutamide differ from its competitors?
   It was the first androgen receptor inhibitor approved for nmCRPC and exhibits a manageable safety profile. It competes primarily with enzalutamide and darolutamide, with comparative efficacy data still emerging.

3. What are the upcoming clinical trials that could impact Apalutamide’s market?
   The TITAN trial results will clarify its role in mHSPC, and ARMOR3-SV could extend its use in castration-resistant settings, fostering broader adoption.

4. Are there significant safety concerns with Apalutamide?
   Overall, it demonstrates a manageable safety profile, with common side effects including fatigue, rash, and hypertension. CNS effects are less frequent compared to enzalutamide.

5. What strategic moves should pharmaceutical companies pursue for Apalutamide?
   Focus on expanding indications via clinical trials, secure regulatory approvals in emerging markets, and develop combination regimens to enhance efficacy and market penetration.

---

References

1. Market Data & Prostate Cancer Drugs Market Size: Grand View Research, 2022.
2. Global Prostate Cancer Incidence: World Health Organization (WHO), 2021.
3. Clinical Trial Data & Outcomes: ClinicalTrials.gov, 2023; Janssen Annual Reports 2022.
4. Regulatory Approvals: FDA, EMA, PMDA, 2018–2021.
5. Comparative Market Analysis: Evaluate Pharma and IQVIA reports, 2022.